Pharmaceutical Executive-08-01-2015

A patient has been prescribed a drug, your company’s drug. What next? Is there an app for that?Step back and think about the patient journey to this point. In the course of the joys and trials of day-to-day living, a patient may be afflicted with early symptoms. Be they minor or severe, a patient hopefully receives a diagnosis, often after missed opportunities and wrong turns than can stretch for years.

The need for biopharma executives to combine a "culture of quality" with value-added processes and improvements in the area drug manufacturing is critical. Here are steps and strategies than can help.

Commercial success for pharma brands now demands proactive strategies and interventions

BIG DATA IS BIG-it’s the one trend in healthcare that demands to be described in superlatives.

Alzheimer’s disease (AD) researchers have seen more than their share of hopefulness and disillusionment over the years. Recent apparent gains targeting one of the disease’s two molecular bull’s-eyes may have reinvigorated drug development, or it may have set developers and investors up for letdown once more. To follow the news coming out of July’s Alzheimer’s Association International Conference in Washington, one had to be prepared for both glass half-full and half-empty interpretations.

Experts from industry and academia probe the changing role of the pharmacoepidemiology function as it grapples with the challenges of big data analytics, tightening drug safety requirements, growing post-approval study burdens, and payer expectations around the application of real-world evidence.

The case of Amgen v. Sandoz signals that preliminary injunctions will play major role in future patent disputes

FDA reform may get tangled up in user fee negotiations, budget debate

The volatility of nation's crisis could pose greater challenges down the line

Despite rising healthcare costs, Algeria, the second-largest pharmaceutical market in Africa, remains optimistic about its pharma sector, which is riding the momentum of recent healthcare reforms. Manufacturing challenges and a growing prevalence of chronic disease, however, offer pause to the bright scenario.